Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.
Reasonable growth potential with mediocre balance sheet.
Share Price & News
How has Ligand Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LGND's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: LGND underperformed the US Biotechs industry which returned 22% over the past year.
Return vs Market: LGND underperformed the US Market which returned 4.3% over the past year.
Price Volatility Vs. Market
How volatile is Ligand Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StIs Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) CEO Being Overpaid?
1 month ago | Simply Wall StVolatility 101: Should Ligand Pharmaceuticals (NASDAQ:LGND) Shares Have Dropped 19%?
2 months ago | Simply Wall StShould You Use Ligand Pharmaceuticals's (NASDAQ:LGND) Statutory Earnings To Analyse It?
Is Ligand Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: LGND ($111.91) is trading above our estimate of fair value ($39.85)
Significantly Below Fair Value: LGND is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: LGND is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: LGND is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LGND's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LGND is good value based on its PB Ratio (2.7x) compared to the US Biotechs industry average (3.6x).
How is Ligand Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LGND is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: LGND is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: LGND's is expected to become profitable in the next 3 years.
Revenue vs Market: LGND's revenue (12.6% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: LGND's revenue (12.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LGND's Return on Equity is forecast to be high in 3 years time
How has Ligand Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LGND is currently unprofitable.
Growing Profit Margin: LGND is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LGND is unprofitable, but has reduced losses over the past 5 years at a rate of 38.1% per year.
Accelerating Growth: Unable to compare LGND's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LGND is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: LGND has a negative Return on Equity (-9.24%), as it is currently unprofitable.
How is Ligand Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: LGND's short term assets ($830.7M) exceed its short term liabilities ($20.4M).
Long Term Liabilities: LGND's short term assets ($830.7M) exceed its long term liabilities ($503.6M).
Debt to Equity History and Analysis
Debt Level: LGND's debt to equity ratio (67.1%) is considered high.
Reducing Debt: LGND's debt to equity ratio has reduced from 598.2% to 67.1% over the past 5 years.
Debt Coverage: LGND's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if LGND's interest payments on its debt are well covered by EBIT.
What is Ligand Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LGND's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LGND's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LGND's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LGND's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LGND's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Higgins (50yo)
Mr. John L. Higgins has been the Chief Executive Officer at Ligand Pharmaceuticals Incorporated since January 16, 2007. He serves as the President and Chief Executive Officer of Moonstone Acquisition, Inc. ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD6.77M) is above average for companies of similar size in the US market ($USD4.72M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
|CEO & Executive Director||13.5yrs||US$6.77m||1.09% $19.6m|
|President & COO||5.5yrs||US$4.24m||0.88% $15.8m|
|Executive VP of Finance & CFO||4.92yrs||US$3.57m||0.084% $1.5m|
|Senior VP||13.25yrs||US$2.03m||0.25% $4.6m|
|Senior Vice President of Investor Relations||no data||no data||no data|
|Director of Corporate Development||no data||no data||no data|
|Senior VP of Human Resources||13.5yrs||no data||no data|
|Senior Vice President of Biology & Scientific Affairs||2.5yrs||no data||no data|
|Senior Vice President of Technical Operations & QA - Capitsol||2.5yrs||no data||no data|
Experienced Management: LGND's management team is seasoned and experienced (5.5 years average tenure).
|CEO & Executive Director||13.5yrs||US$6.77m||1.09% $19.6m|
|Independent Chairman||13.33yrs||US$369.90k||0.17% $3.0m|
|Independent Director||13.33yrs||US$349.90k||0.31% $5.6m|
|Independent Director||9.42yrs||US$342.40k||0.15% $2.8m|
|Independent Director||9.75yrs||US$344.90k||0.17% $3.0m|
|Independent Director||11.92yrs||US$359.90k||0.15% $2.7m|
|Independent Director||13.83yrs||US$352.40k||0.46% $8.2m|
|Scientific Advisor||no data||no data||no data|
|Independent Director||0.75yr||US$457.73k||0.014% $253.1k|
|Independent Director||2.92yrs||US$344.90k||0.019% $343.8k|
Experienced Board: LGND's board of directors are seasoned and experienced ( 11.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: LGND insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ligand Pharmaceuticals Incorporated's company bio, employee growth, exchange listings and data sources
- Name: Ligand Pharmaceuticals Incorporated
- Ticker: LGND
- Exchange: NasdaqGM
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.796b
- Shares outstanding: 16.05m
- Website: https://www.ligand.com
Number of Employees
- Ligand Pharmaceuticals Incorporated
- 3911 Sorrento Valley Boulevard
- Suite 110
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LGND||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Nov 1994|
|LGDN||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 1994|
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; and Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations. It also offers bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Minnebro for the treatment of hypertension; and Bryxta for non-small cell lung cancer. The company’s partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/01 23:54|
|End of Day Share Price||2020/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.